Glioblastoma multiforme (GBM) is a highly aggressive type of primary brain tumor that can grow fatally in the brain and is influenced by homeobox gene expression. Curcumin, a substance that has been identified from Curcuma longa L., shows potential as an antitumor agent with minimal side effects. This study aimed to examine the impact of nanocurcumin on the survival of cells, homeobox gene expression, and the proportions of living cells, necrotic cells, and apoptotic cells. Nanocurcumin is formulated for use in drug delivery to elevate curcumin efficacy. GBM cells (U87) were cultured and subjected to varying concentrations of nanocurcumin to assess cell viability. Subsequently, the cells were subjected to specific doses of nanocurcumin for treatment (25, 50, and 100 μg/mL) along with TMZ 300 μM, and gene expression levels of HOXA5, HOXB1, HOXC9, and HOXC10 were determined using qRT-PCR. Flow cytometry was used to measure live, necrotic, and apoptotic cells. The viability test showed that nanocurcumin decreased U87 cell viability with a 44.06 μg/mL IC50 value. Treatment with 100 μg/mL nanocurcumin downregulated the expression of HOXA5, HOXC9, and HOXC10 genes while increasing HOXB1 gene expression. In addition, treatment with 50 μg/mL nanocurcumin decreased the proportion of live cells, increased the apoptotic cell fraction, and controlled the ratio of necrotic cells in U87. Nanocurcumin shows promising potential as a therapy for glioblastoma. Lastly, the therapeutic approach for the alternative cure of GBM tumors highlighted the prospective potential of nanocurcumin.